UPDATE 1-FDA says ulcer drugs may raise diarrhea risk
* Says patients taking PPIs should be tested for CDAD
* Says PPIs may increase risk of CDAD
Feb 8 (Reuters) - U.S. health regulators said ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of clostridium difficile-associated diarrhea (CDAD).
Clostridium difficile is a bacteria naturally present in the gut and can cause colitis and other intestinal conditions.
The U.S. Food and Drug Administration said patients who develop diarrhea after taking these drugs should be checked for CDAD.
The drugs called proton pump inhibitors (PPIs) are widely used for treating ulcers, acid reflux and other conditions.
Other PPIs sold by prescription include Takeda Pharmaceutical Co Ltd's Dexilant and Prevacid, AstraZeneca's Prilosec and Vimovo, Santarus Inc's Zegerid, and Johnson & Johnson and Eisai Co Ltd's AcipHex.
Generic versions of Prevacid and Prilosec also are available.
Details were released on the FDA website at
- Google bus blocked in San Francisco gentrification protest
- Thai PM urges protesters to take part in election |
- North Korea's 'reign of terror' worries South's leader
- Obama, Castro shake hands as world says farewell to peacemaker Mandela |
- Rare Singapore riot forces soul searching over foreign workers